Issue 98, 2021

Organometallic small molecule kinase inhibitors – direct incorporation of Re and 99mTc into Opaganib®

Abstract

[(η5-Cp)ReI(CO)3] was incorporated into the kinase inhibitor Opaganib®. The resulting bioorganometallic complex showed a similar anti-cancer activity to Opaganib® against PC-3 cancer cells. The IC50 value for the kinase SK2 is 30x higher than that of Opaganib®. The 99mTc homologue was synthesized, completing a matched-pair for molecular theranostics.

Graphical abstract: Organometallic small molecule kinase inhibitors – direct incorporation of Re and 99mTc into Opaganib®

Supplementary files

Article information

Article type
Communication
Submitted
08 Jul 2021
Accepted
19 Nov 2021
First published
20 Nov 2021
This article is Open Access
Creative Commons BY license

Chem. Commun., 2021,57, 13349-13352

Organometallic small molecule kinase inhibitors – direct incorporation of Re and 99mTc into Opaganib®

R. Lengacher, Y. Wang, H. Braband, O. Blacque, G. Gasser and R. Alberto, Chem. Commun., 2021, 57, 13349 DOI: 10.1039/D1CC03678E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements